Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heads Up: Upadacitinib vs Dupilumab in Atopic Dermatitis
NCT03738397Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of upadacitinib in atopic dermatitis (AD), sponsored by AbbVie Inc.. Started Feb 2019; status: completed.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03738397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03738397.